Characterisation of Cancer Stem Cell Populations in Primary Glioblastoma Cultures: A Review
DOI:
https://doi.org/10.5281/zenodo.22237872Keywords:
glioblastoma; cancer stem cells; CD133; limiting dilution; tumour heterogeneityAbstract
Background: Glioblastoma contains cells that initiate tumours at low dose and resist therapy. How that population should be
defined, and whether it is a fixed compartment, remains contested.
Objective: To review how cancer stem cell populations are characterised in primary glioblastoma culture, and what the
markers and assays establish.
Methods: Narrative review of primary studies on glioma stem cell isolation, culture conditions, marker validation, functional
assays and heterogeneity.
Findings: As few as 100 CD133-positive cells initiated a serially transplantable tumour where 100,000 negative cells did not,
but stem-like CD133-negative cells were later shown to sustain a subset of tumours, so the marker is neither necessary nor
sufficient. Serum-cultured lines diverge from the parent tumour, while serum-free bFGF and EGF culture preserves genotype
and phenotype. Single-cell sequencing describes four interconverting states rather than fixed types.
Conclusions: Functional assays, not surface markers, define the population, and plasticity makes that definition conditional.
References
Reynolds, B.A., Weiss, S. (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science, 255(5052): 1707-1710.
Hemmati, H.D., Nakano, I., Lazareff, J.A., Masterman-Smith, M., Geschwind, D.H., Bronner-Fraser, M., et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A, 100(25): 15178-15183.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., et al. (2004) Identification of human brain tumour initiating cells. Nature, 432(7015): 396-401.
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res, 64(19): 7011-7021.
Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., et al. (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol, 23(8): 1231-1251.
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9(5): 391-403.
Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell, 4(6): 568-580.
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P.J., et al. (2007) CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res, 67(9): 4010-4015.
Lathia, J.D., Gallagher, J., Heddleston, J.M., Wang, J., Eyler, C.E., Macswords, J., et al. (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell, 6(5): 421-432.
Bao, S., Wu, Q., Li, Z., Sathornsumetee, S., Wang, H., McLendon, R.E., et al. (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res, 68(15): 6043-6048.
Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M.A., et al. (2010) TGF-beta receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell, 18(6): 655-668.
Mao, P., Joshi, K., Li, J., Kim, S.H., Li, P., Santana-Santos, L., et al. (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A, 110(21): 8644-8649.
Hu, Y., Smyth, G.K. (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods, 347(1-2): 70-78.
MacLeod, G., Bozek, D.A., Rajakulendran, N., Monteiro, V., Ahmadi, M., Steinhart, Z., et al. (2019) Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep, 27(3): 971-986.
Lan, X., Jorg, D.J., Cavalli, F.M.G., Richards, L.M., Nguyen, L.V., Vanner, R.J., et al. (2017) Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature, 549(7671): 227-232.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488(7412): 522-526.
Suva, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wang, H., Rivera, M.N., et al. (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell, 157(3): 580-594.
Bhat, K.P.L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., et al. (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell, 24(3): 331-346.
Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190): 1396-1401.
Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1): 98-110.
Neftel, C., Laffy, J., Filbin, M.G., Hara, T., Shore, M.E., Rahme, G.J., et al. (2019) An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 178(4): 835-849.
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell, 11(1): 69-82.
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15(6): 501-513.
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120): 756-760.
Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352(10): 997-1003.
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352(10): 987-996.
Hubert, C.G., Rivera, M., Spangler, L.C., Wu, Q., Mack, S.C., Prager, B.C., et al. (2016) A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res, 76(8): 2465-2477.
Jacob, F., Salinas, R.D., Zhang, D.Y., Nguyen, P.T.T., Schnoll, J.G., Wong, S.Z.H., et al. (2020) A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell, 180(1): 188-204.
